{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:41:34Z","timestamp":1789684894314,"version":"4.0.1"},"reference-count":82,"publisher":"AIP Publishing","issue":"1","funder":[{"DOI":"10.13039\/100011132","name":"Rutgers, The State University of New Jersey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pubs.aip.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:p>Chronic myelogenous\/myeloid leukemia (CML) is a type of cancer of bone marrow that arises from hematopoietic stem cells and affects millions of people worldwide. Eighty-five percent of the CML cases are diagnosed during chronic phase, most of which are detected through routine tests. Leukocytes, micro-Ribonucleic Acids, and myeloid markers are the primary biomarkers for CML diagnosis and are mainly detected using real-time reverse transcription polymerase chain reaction, flow cytometry, and genetic testing. Though multiple therapies have been developed to treat CML, early detection still plays a pivotal role in the overall patient survival rate. The current technologies used for CML diagnosis are costly and are confined to laboratory settings which impede their application in the point-of-care settings for early-stage detection of CML. This study provides detailed analysis and insights into the significance of CML, patient symptoms, biomarkers used for testing, and best possible detection techniques responsible for the enhancement in survival rates. A critical and detailed review is provided around potential microfluidic devices that can be adapted to detect the biomarkers associated with CML while enabling point-of-care testing for early diagnosis of CML to improve patient survival rates.<\/jats:p>","DOI":"10.1063\/5.0172550","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T19:14:23Z","timestamp":1706210063000},"update-policy":"https:\/\/doi.org\/10.1063\/aip-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Enabling biomedical technologies for chronic myelogenous leukemia (CML) biomarkers detection"],"prefix":"10.1063","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2036-2628","authenticated-orcid":false,"given":"Meenakshi","family":"Pinnenti","sequence":"first","affiliation":[{"name":"Department of Electrical & Computer Engineering, Rutgers, The State University of New Jersey 1 , New Brunswick, New Jersey 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-7709","authenticated-orcid":false,"given":"Muhammad Ahsan","family":"Sami","sequence":"additional","affiliation":[{"name":"Department of Electrical & Computer Engineering, Rutgers, The State University of New Jersey 1 , New Brunswick, New Jersey 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1562-855X","authenticated-orcid":false,"given":"Umer","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Electrical & Computer Engineering, Rutgers, The State University of New Jersey 1 , New Brunswick, New Jersey 08901, USA"},{"name":"Global Health Institute, Rutgers, The State University of New Jersey 2 , New Brunswick, New Jersey 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"317","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"2024012519141712700_c1","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia 2022 update on diagnosis, therapy, and monitoring","volume":"97","year":"2022","journal-title":"Am. J. Hematol."},{"key":"2024012519141712700_c2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"2024012519141712700_c3"},{"key":"2024012519141712700_c4","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","journal-title":"Blood"},{"key":"2024012519141712700_c5","author":"MedlinePlus [Internet]"},{"key":"2024012519141712700_c6","volume-title":"Genes and Disease [Internet]","author":"National Center for Biotechnology Information (US)","year":"1998"},{"key":"2024012519141712700_c7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood.V51.5.843.843","article-title":"Chronologic sequence in appearance of clinical and laboratory findings characteristic of chronic myelocytic leukemia","volume":"51","year":"1978","journal-title":"Blood"},{"key":"2024012519141712700_c8","author":"MedlinePlus [Internet]"},{"key":"2024012519141712700_c9","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1172\/JCI33032","article-title":"The legacy of the Philadelphia chromosome","volume":"117","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2024012519141712700_c10","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","year":"1999","journal-title":"J. Exp. Med."},{"key":"2024012519141712700_c11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0609.2011.01586.x","article-title":"ABL1 fusion genes in hematological malignancies: A review","volume":"86","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"2024012519141712700_c12","doi-asserted-by":"publisher","first-page":"12516","DOI":"10.3390\/ijms222212516","article-title":"Genetic biomarkers in chronic myeloid leukemia: What have we learned so far?","volume":"22","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"2024012519141712700_c13","author":"Mayo Clinic"},{"key":"2024012519141712700_c14","author":"Douglas.Kale@propath.com"},{"key":"2024012519141712700_c15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","article-title":"Chronic myelogenous leukemia: A concise update","volume":"82","year":"1993","journal-title":"Blood"},{"key":"2024012519141712700_c16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/biology10020118","article-title":"Future approaches for treating chronic myeloid leukemia: CRISPR therapy","volume":"10","year":"2021","journal-title":"Biology"},{"key":"2024012519141712700_c17","author":"American Society of Clinical Oncology (ASCO)"},{"key":"2024012519141712700_c18","author":"CML phases and Prognostic Factors"},{"key":"2024012519141712700_c19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","year":"2015","journal-title":"Ann. Hematol."},{"key":"2024012519141712700_c20","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: Mechanisms of blastic transformation","volume":"120","year":"2010","journal-title":"J. Clin. Invest."},{"key":"2024012519141712700_c21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11899-012-0114-5","article-title":"Genetic mechanisms of chronic myeloid leukemia blastic transformation","volume":"7","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2024012519141712700_c22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukemia as a model of disease evolution in human cancer","volume":"7","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"2024012519141712700_c23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.yexmp.2007.05.005","article-title":"Diminished CD10, CD13, and CD15 expression in a differentiated granulocyte population in CML","volume":"83","year":"2007","journal-title":"Exp. Mol. Pathol."},{"key":"2024012519141712700_c24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/0145-2126(91)90029-S","article-title":"Expression of hematopoietic progenitor cell-associated antigen CD34 in chronic myeloid leukemia","volume":"15","year":"1991","journal-title":"Leukemia Research"},{"key":"2024012519141712700_c25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1172\/JCI112267","article-title":"Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implications for prostaglandin E resistance in chronic myeloid leukemia","volume":"77","year":"1986","journal-title":"J. Clin. Invest."},{"key":"2024012519141712700_c26","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","year":"2021","journal-title":"Leukemia"},{"key":"2024012519141712700_c27","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood.V78.7.1834.1834","article-title":"CD10 (CALLA)\/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation","volume":"78","year":"1991","journal-title":"Blood"},{"key":"2024012519141712700_c28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3324\/haematol.2010.035006","article-title":"CD34(+)\/CD38(\u2212) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin","volume":"97","year":"2012","journal-title":"Haematologica"},{"key":"2024012519141712700_c29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1200\/JCO.2016.67.0893","article-title":"Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia","volume":"35","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"2024012519141712700_c30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","year":"2014","journal-title":"Biomark. Res."},{"key":"2024012519141712700_c31","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1182\/blood-2012-12-475194","article-title":"Monoclonal antibody targeting of IL-3 receptor \u03b1 with CSL362 effectively depletes CML progenitor and stem cells","volume":"123","year":"2014","journal-title":"Blood"},{"key":"2024012519141712700_c32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ph13120441","article-title":"14-3-3\u03c3 and its modulators in cancer","volume":"13","year":"2020","journal-title":"Pharmaceuticals"},{"key":"2024012519141712700_c33","article-title":"Chronic myelogenous leukemia. [updated 2023 Jan 16]","volume-title":"StatPearls [Internet]","year":"2023"},{"key":"2024012519141712700_c34","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1182\/blood-2010-12-322537","article-title":"BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription","volume":"118","year":"2011","journal-title":"Blood"},{"key":"2024012519141712700_c35","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00277-016-2721-z","article-title":"BCR-ABL-positive acute myeloid leukemia: A new entity? Analysis of clinical and molecular features","volume":"95","year":"2016","journal-title":"Ann. Hematol."},{"key":"2024012519141712700_c36","doi-asserted-by":"publisher","first-page":"949","DOI":"10.4149\/neo_2015_115","article-title":"microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia","volume":"62","year":"2015","journal-title":"Neoplasma"},{"key":"2024012519141712700_c37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.blre.2016.11.003","article-title":"MicroRNA: Defining a new niche in leukemia","volume":"31","year":"2017","journal-title":"Blood Rev."},{"key":"2024012519141712700_c38","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3389\/fonc.2020.01544","article-title":"Comparison of microRNA expression profile in chronic myeloid leukemia patients newly diagnosed and treated by allogeneic hematopoietic stem cell transplantation","volume":"10","year":"2020","journal-title":"Front. Oncol."},{"key":"2024012519141712700_c39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ddr.21266","article-title":"miRNAs as biomarkers in chronic myelogenous leukemia","volume":"76","year":"2015","journal-title":"Drug Dev. Res."},{"key":"2024012519141712700_c40","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","article-title":"Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34\u2009+\u2009cells increases USF2-mediated cell growth","volume":"6","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"2024012519141712700_c41","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","article-title":"Expression of the MIR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells","volume":"109","year":"2007","journal-title":"Blood"},{"key":"2024012519141712700_c42","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.lrr.2021.100257","article-title":"Circulating miRNAs can serve as potential diagnostic biomarkers in chronic myelogenous leukemia patients","volume":"16","year":"2021","journal-title":"Leuk. Res. Rep."},{"key":"2024012519141712700_c43","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2217\/fon-2018-0741","article-title":"Differential expression profiles and functional analysis of plasma miRNAs associated with chronic myeloid leukemia phases","volume":"15","year":"2019","journal-title":"Future Oncology"},{"key":"2024012519141712700_c44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3892\/br.2016.747","article-title":"Emerging role of microRNA-21 in cancer","volume":"5","year":"2016","journal-title":"Biomed. Rep."},{"key":"2024012519141712700_c45","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.31557\/APJCP.2019.20.8.2379","article-title":"microRNA-21 expression as prognostic and therapeutic response marker in chronic myeloid leukaemia patients","volume":"20","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2024012519141712700_c46","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2174\/13894501113149990185","article-title":"Targeting Mir-21 induces autophagy and chemosensitivity of leukemia cells","volume":"14","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"2024012519141712700_c47","doi-asserted-by":"publisher","first-page":"9666","DOI":"10.1038\/s41598-019-46132-9","article-title":"MicroRNA signature refine response prediction in CML","volume":"9","year":"2019","journal-title":"Sci. Rep."},{"key":"2024012519141712700_c48","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.yexcr.2013.02.002","article-title":"Mir-29B suppresses CML cell proliferation and induces apoptosis via regulation of BCR\/ABL1 protein","volume":"319","year":"2013","journal-title":"Exp. Cell Res."},{"key":"2024012519141712700_c49","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s12288-019-01241-3","article-title":"MicroRNA 30a mediated autophagy and imatinib response in Egyptian chronic myeloid leukemia patients","volume":"36","year":"2020","journal-title":"Indian J. Hematol. Blood Transfus"},{"key":"2024012519141712700_c50","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/leu.2012.65","article-title":"Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells","volume":"26","year":"2012","journal-title":"Leukemia"},{"key":"2024012519141712700_c51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.leukres.2012.12.003","article-title":"Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia","volume":"37","year":"2013","journal-title":"Leuk. Res."},{"key":"2024012519141712700_c52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/onc.2012.557","article-title":"BCR-ABL\/GATA1\/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia","volume":"33","year":"2014","journal-title":"Oncogene"},{"key":"2024012519141712700_c53","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","article-title":"Genetic and epigenetic silencing of MicroRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression","volume":"13","year":"2008","journal-title":"Cancer Cell"},{"key":"2024012519141712700_c54","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.leukres.2013.07.019","article-title":"Imatinib induces demethylation of Mir-203 gene: An epigenetic mechanism of anti-tumor effect of imatinib","volume":"37","year":"2013","journal-title":"Leuk. Res."},{"key":"2024012519141712700_c55","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1038\/srep12460","article-title":"MicroRNA-320a acts as a tumor suppressor by targeting BCR\/ABL oncogene in chronic myeloid leukemia","volume":"5","year":"2015","journal-title":"Sci. Rep."},{"key":"2024012519141712700_c56","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.1021\/acsomega.1c00035","article-title":"Mir-486-5p: A prognostic biomarker for chronic myeloid leukemia","volume":"6","year":"2021","journal-title":"ACS Omega"},{"key":"2024012519141712700_c57"},{"key":"2024012519141712700_c58","volume-title":"Clinical Hematology: Theory and Procedures","year":"2005"},{"key":"2024012519141712700_c59","volume-title":"Veterinary Technician's Handbook of Laboratory Procedures","year":"2022"},{"key":"2024012519141712700_c60","doi-asserted-by":"publisher","first-page":"e0133489","DOI":"10.1371\/journal.pone.0133489","article-title":"Counting white blood cells from a blood smear using Fourier ptychographic microscopy","volume":"10","year":"2015","journal-title":"PloS One"},{"key":"2024012519141712700_c61","volume-title":"Practical Flow Cytometry","year":"2005"},{"key":"2024012519141712700_c62","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1088\/0967-3334\/26\/3\/R02","article-title":"Microfluidics for flow cytometric analysis of cells and particles","volume":"26","year":"2005","journal-title":"Physiol. Meas."},{"key":"2024012519141712700_c63","first-page":"345","article-title":"Sudden blast phase in pediatric chronic myeloid leukemia-chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: Can it be considered a warning sign","year":"2021","journal-title":"Cytometry Part B: Clinical Cytometry 100"},{"key":"2024012519141712700_c64","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL","volume":"7","year":"2005","journal-title":"Cancer Cell"},{"key":"2024012519141712700_c65","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1097\/HS9.0000000000000496","article-title":"Digital PCR for BCR-ABL1 quantification in CML: Current applications in clinical practice","volume":"4","year":"2020","journal-title":"Hemasphere"},{"key":"2024012519141712700_c66","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"2024012519141712700_c67","author":"Lexi-Comp Inc.,"},{"key":"2024012519141712700_c68","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1093\/nar\/gkn705","article-title":"Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms","volume":"36","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"2024012519141712700_c69","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1741-7007-9-34","article-title":"Microarrays, deep sequencing and the true measure of the transcriptome","volume":"9","year":"2011","journal-title":"BMC Biol."},{"key":"2024012519141712700_c70","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jcmm.12236","article-title":"Methodological challenges in utilizing miRNAs as circulating biomarkers","volume":"18","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"2024012519141712700_c71","doi-asserted-by":"publisher","first-page":"214ra170","DOI":"10.1126\/scitranslmed.3006870","article-title":"Microfluidic CD4+ and CD8+ T lymphocyte counters for point-of-care HIV diagnostics using whole blood","volume":"5","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2024012519141712700_c72a","doi-asserted-by":"publisher","first-page":"15949","DOI":"10.1038\/ncomms15949","article-title":"A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification","volume":"8","year":"2017","journal-title":"Nat. Commun."},{"key":"2024012519141712700_c72b","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","year":"1975","journal-title":"Blood"},{"key":"2024012519141712700_c73","doi-asserted-by":"publisher","first-page":"115661","DOI":"10.1016\/j.bios.2023.115661","article-title":"Multi-modal sensing with integrated machine learning to differentiate specific leukocytes targeted by electrically sensitive hybrid particles","volume":"241","year":"2023","journal-title":"Biosens. Bioelectron."},{"key":"2024012519141712700_c74","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41598-017-18725-9","article-title":"Multifunctional microfluidic chip for optical nanoprobe based RNA detection\u2014Application to chronic myeloid leukemia","volume":"8","year":"2018","journal-title":"Sci. Rep."},{"key":"2024012519141712700_c75","doi-asserted-by":"publisher","first-page":"12428","DOI":"10.1021\/acs.analchem.9b03061","article-title":"Visual detection of fusion genes by ligation-triggered isothermal exponential amplification: A point-of-care testing method for highly specific and sensitive quantitation of fusion genes with a smartphone","volume":"91","year":"2019","journal-title":"Anal. Chem."},{"key":"2024012519141712700_c76","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1021\/ac400896j","article-title":"High-throughput microfluidic single-cell digital polymerase chain reaction","volume":"85","year":"2013","journal-title":"Anal. Chem."},{"key":"2024012519141712700_c77","doi-asserted-by":"publisher","first-page":"120996","DOI":"10.1016\/j.talanta.2020.120996","article-title":"A microfluidic paper-based laser-induced fluorescence sensor based on duplex-specific nuclease amplification for selective and sensitive detection of miRNAs in cancer cells","volume":"216","year":"2020","journal-title":"Talanta"},{"key":"2024012519141712700_c78","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1021\/acs.analchem.0c04896","article-title":"Attomolar-level ultrasensitive and multiplex microRNA detection enabled by a nanomaterial locally assembled microfluidic biochip for cancer diagnosis","volume":"93","year":"2021","journal-title":"Anal. Chem."},{"key":"2024012519141712700_c79","doi-asserted-by":"publisher","first-page":"1905311","DOI":"10.1002\/adma.201905311","article-title":"CRISPR\/Cas13a-powered electrochemical microfluidic biosensor for nucleic acid amplification-free MIRNA diagnostics","volume":"31","year":"2019","journal-title":"Adv. Mater."},{"key":"2024012519141712700_c80","doi-asserted-by":"publisher","first-page":"112887","DOI":"10.1016\/j.bios.2020.112887","article-title":"CRISPR-powered electrochemical microfluidic multiplexed biosensor for target amplification-free miRNA diagnostics","volume":"177","year":"2021","journal-title":"Biosens. Bioelectron."},{"key":"2024012519141712700_c81","doi-asserted-by":"publisher","first-page":"28933","DOI":"10.1021\/acsami.3c03399","article-title":"Ultrasensitive detection of MIRNA via CRISPR\/Cas12a coupled with strand displacement amplification reaction","volume":"15","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"}],"container-title":["Biomicrofluidics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.aip.org\/aip\/bmf\/article-pdf\/doi\/10.1063\/5.0172550\/18930309\/011501_1_5.0172550.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.aip.org\/aip\/bmf\/article-pdf\/doi\/10.1063\/5.0172550\/18930309\/011501_1_5.0172550.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T19:14:30Z","timestamp":1706210070000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.aip.org\/bmf\/article\/18\/1\/011501\/3132640\/Enabling-biomedical-technologies-for-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1063\/5.0172550","relation":{},"ISSN":["1932-1058"],"issn-type":[{"value":"1932-1058","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2024,1,1]]},"article-number":"011501"}}